Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Orchestrating organotropism: miRNA-driven mechanisms of site-specific metastasis in triple-negative breast cancer (Review)

Bu R., Bo L.

Narrative Review, published in Oncol Lett (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Oncol Lett (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41822558
PMCID
PMC12977313
DOI
10.3892/ol.2026.15504

Abstract (original English)

Triple-negative breast cancer (TNBC), characterized by its aggressive nature and poor prognosis, exhibits a pronounced propensity for organ-specific metastasis, which remains the primary cause of treatment failure and mortality. The present review synthesizes current knowledge on the pivotal role of microRNAs (miRNAs/miRs), particularly those shuttled via tumor-derived exosomes, in orchestrating the complex molecular mechanisms underlying TNBC metastasis to the brain, bone, liver and lungs. In addition, the review highlights how specific miRNAs function as master regulators of organotropic metastasis by facilitating pre-metastatic niche (PMN) formation through miRNA-target gene-microenvironment remodeling cascades. Key mechanisms discussed include: Brain metastasis, in which miR-105 disrupts the blood-brain barrier by targeting zonula occludens protein 1 and miR-19a activates astrocytic STAT3 signaling to promote tumor extravasation and survival; bone metastasis, in which miR-218-5p disrupts the osteoprotegerin/receptor activator of nuclear factor κB ligand balance and miR-21 drives a self-perpetuating osteolysis-growth factor-tumor proliferation loop via programmed cell death 4/nuclear factor of activated T cells 1 and TGF-β feedback; liver metastasis, in which miR-122 reprograms the host metabolism by suppressing pyruvate kinase M2 and O-GlcNAc transferase, and contributes to

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.